« Return to News | Drug Sponsors

The Research Network operates from former Pfizer site

Thursday, September 1, 2011 10:25 AM

A company set up by a group of former Pfizer employees is one of the first businesses to be based at the east Kent site which Pfizer is leaving, according to BBC Mobile.

The Research Network, which employs seven former Pfizer workers, is operating from Discovery Park in Sandwich.

In February, the drugs giant said it was closing its Sandwich base. The government recently announced the site is to become an enterprise zone.

Andrew McElroy, chief executive of The Research Network, was made redundant from Pfizer in July. "There's a lot of change happening at the Pfizer site and as other Pfizer groups disband we're growing; we're a small island there of activity that's expanding,” said McElroy.

"We're one of probably about a dozen different spin out groups, we just happen to be the first to occupy some offices there,” McElroy said.

The Research Network works to connect staff and businesses across the pharmaceutical industry.

McElroy said, "It's a bit like a dating agency for scientists.”  He continued, "We'll find the right person to work with, the right company to work with and then we'll help with the logistics.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.